IRIS
ZANGHI', AURORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 611
NA - Nord America 365
AS - Asia 117
OC - Oceania 5
SA - Sud America 2
Totale 1.100
Salva come PNG Salva come JPEG
Nazione #
IE - Irlanda 381
US - Stati Uniti d'America 364
IT - Italia 97
SE - Svezia 71
SG - Singapore 44
CN - Cina 42
FI - Finlandia 27
TR - Turchia 10
GB - Regno Unito 9
DE - Germania 6
IR - Iran 6
HK - Hong Kong 5
AU - Australia 4
BE - Belgio 4
PK - Pakistan 4
CH - Svizzera 3
IN - India 3
NL - Olanda 3
RO - Romania 2
RU - Federazione Russa 2
AM - Armenia 1
AR - Argentina 1
AT - Austria 1
BR - Brasile 1
CA - Canada 1
DK - Danimarca 1
FR - Francia 1
JP - Giappone 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
UA - Ucraina 1
Totale 1.100
Salva come PNG Salva come JPEG
Città #
Dublin 381
Chandler 87
Nyköping 70
Princeton 39
Singapore 33
Helsinki 27
Wilmington 25
Los Angeles 13
Des Moines 11
Ashburn 9
Kocaeli 8
Rome 8
Guangzhou 7
Milan 7
Santa Clara 7
Naples 6
Seattle 6
Bari 4
Cedar Knolls 4
London 4
Long Beach 4
San Severo 4
Tehran 4
Tsuen Wan 4
Jiaxing 3
Norwalk 3
Shenzhen 3
Washington 3
Adelaide 2
Ankara 2
Ann Arbor 2
Brussels 2
Catania 2
Gavere 2
Genoa 2
Karachi 2
Manfredonia 2
Maslianico 2
Nanjing 2
New York 2
Orta Nova 2
Padova 2
Pimonte 2
Pisa 2
Potenza 2
Pune 2
Rui'an 2
Spinazzola 2
Wuhan 2
Xuzhou 2
Zibo 2
Boardman 1
Buenos Aires 1
Buffalo 1
Catanzaro 1
Cava de' Tirreni 1
Caxias do Sul 1
Central 1
Chicago 1
Chisinau 1
Clearwater 1
Coventry 1
Davis 1
Edinburgh 1
Foggia 1
Frankfurt am Main 1
Hangzhou 1
Hefei 1
Jalandhar 1
Kemerovo 1
Kish 1
Logan 1
Melbourne 1
Misilmeri 1
Nara 1
Nuremberg 1
Ottawa 1
Paris 1
Pinehaven 1
Pitesti 1
Quanzhou 1
Reston 1
Ruvo di Puglia 1
Shanghai 1
Taunsa 1
Vancouver 1
Vienna 1
Yerevan 1
Totale 867
Salva come PNG Salva come JPEG
Nome #
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 63
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 54
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 50
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 46
Management of dysphagia in multiple sclerosis: current best practice 45
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 44
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 40
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 39
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 38
Can new chemical therapies improve the management of multiple sclerosis in children? 38
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 35
An update on the safety of treating relapsing-remitting multiple sclerosis 32
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 30
Palliative care in progressive multiple sclerosis 27
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study 27
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 26
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 26
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 25
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 25
Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies 24
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 24
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 24
Switching therapy: how and why in a real word setting cohort of persons with multiple sclerosis in Catania 23
Switching disease-modifying therapy in multiple sclerosis: escalation therapy has not an advantage on switching among same line drugs 23
Real-world comparison of safety profile in two groups of relapsing remitting multiple sclerosis on dimethyl-fumarate and teriflunomide therapy: preliminary results of a multicenter, prospective study 23
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 22
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 21
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 21
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 21
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 20
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 20
Personalized Therapy in Multiple Sclerosis: state of art and future perspectives 20
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis Patients 20
Real-world comparison of Dimethyl-fumarate and teriflunomide in treatment-naive and non responders patients with relapsing remitting multiple sclerosis: preliminary data of a multicenter, prospectie study 20
Monocytic myeloid derived suppressor cells in hematological malignancies 20
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience 19
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives 19
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 18
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience 18
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs 18
Pharmacoeconomics of synthetic therapies for multiple sclerosis 18
Real-World comparison of reasons for changing treatment to dimethyl-fymarate or teriflunomide in non responders patients with relapsing remitting multiple sclerosis: preliminary results of a multicenter prospective study 17
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment 15
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 15
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience 14
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 13
Relapse-associated worsening in a real-life multiple sclerosis cohort: The role of age and pyramidal phenotype 13
Myeloid-derived Suppressor Cells and Multiple Sclerosis 12
MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study 10
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 9
Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study 9
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series 8
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 8
New treatment targets in multiple sclerosis therapy 7
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 6
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 6
Neural precursor cells tune striatal connectivity through the release of IGFBPL1 6
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey 4
Totale 1.338
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.917
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.917
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202125 0 0 0 0 0 0 0 0 0 24 0 1
2021/2022231 5 0 1 0 95 5 7 14 26 16 4 58
2022/2023722 60 18 39 47 14 44 2 37 413 19 17 12
2023/2024219 15 29 13 17 36 11 18 35 21 9 9 6
2024/2025141 42 35 38 12 14 0 0 0 0 0 0 0
Totale 1.338